269 results on '"Jakopin, Žiga"'
Search Results
2. In silico profiling of endocrine-disrupting potential of bisphenol analogues and their halogenated transformation products
3. Environmental contamination status with common ingredients of household and personal care products exhibiting endocrine-disrupting potential
4. Distinctive Immune Signatures Driven by Structural Alterations in Desmuramylpeptide NOD2 Agonists.
5. Galectin-8N-Selective 4‑Halophenylphthalazinone-Galactals Double π‑Stack in a Unique Pocket.
6. Benzimidazole–galactosides bind selectively to the Galectin-8 N-Terminal domain: Structure-based design and optimisation
7. Discovery of 2,3-Diaminoindole Derivatives as a Novel Class of NOD Antagonists
8. Does targeting Arg98 of FimH lead to high affinity antagonists?
9. Preliminary results on novel adjuvant combinations suggest enhanced immunogenicity of whole inactivated pandemic influenza vaccines.
10. Structural features and functional activities of benzimidazoles as NOD2 antagonists
11. Risks associated with fat burners: A toxicological perspective
12. Blockade of Stearoyl-CoA-desaturase 1 activity reverts resistance to cisplatin in lung cancer stem cells
13. Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity
14. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors
15. Structural features of subtype-selective EP receptor modulators
16. Identification of indole scaffold-based dual inhibitors of NOD1 and NOD2
17. In vitro investigation of immunomodulatory activities of selected UV-filters
18. Structural requirements of acylated Gly-l-Ala-d-Glu analogs for activation of the innate immune receptor NOD2
19. Investigating Novel Adjuvant Combinations to Enhance Immunogenicity of Whole Inactivated Pandemic Influenza Vaccines
20. Lipidation of NOD2 Agonists with Adamantane and Stearoyl Moieties Differentially Regulates Their In Vivo Adjuvant Activity
21. Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune Potentiators
22. Benzimidazole-galactosides bind selectively to the galectin-8 N-terminal domain
23. Halogenated ingredients of household and personal care products as emerging endocrine disruptors
24. Substituted 4-phenyl-2-aminoimidazoles and 4-phenyl-4,5-dihydro-2-aminoimidazoles as voltage-gated sodium channel modulators
25. Synthesis of conformationally constrained γ-d-glutamyl-meso-diaminopimelic acid derivatives as ligands of nucleotide-binding oligomerization domain protein 1 (Nod1)
26. Novel Scaffolds for Modulation of NOD2 Identified by Pharmacophore-Based Virtual Screening
27. Nucleotide-Binding Oligomerization Domain 1/Toll-Like Receptor 4 Co-Engagement Promotes Non-Specific Immune Response Against K562 Cancer Cells
28. Discovery of Desmuramylpeptide NOD2 Agonists with Single-Digit Nanomolar Potency
29. Environmental contamination status with common ingredients of household and personal care products
30. Front Cover: Selective Monovalent Galectin‐8 Ligands Based on 3‐Lactoylgalactoside (ChemMedChem 3/2022)
31. THP-1 cells and pro-inflammatory cytokine production
32. Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs
33. Design and synthesis of novel 3-triazolyl-1-thiogalactosides as galectin-1, -3 and -8 inhibitors
34. Selective Galectin‐8N Ligands: The Design and Synthesis of Phthalazinone‐d‐Galactals
35. Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain
36. Selective Monovalent Galectin‐8 Ligands Based on 3‐Lactoylgalactoside
37. Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their In Vivo Adjuvant Activity
38. Mixed Adjuvant Formulation Based on Peptide Hydrogel and Desmuramyl Peptides: Preparation and Influence on Specific Immune Reaction
39. Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation
40. Nucleotide-Binding Oligomerization Domain 1/Toll-Like Receptor 4 Co-Engagement Promotes Non-Specific Immune Response Against K562 Cancer Cells.
41. Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation
42. OVERVIEW OF ANTIVIRAL DRUGS AGAINST SARS-CoV-2 FOR THE TREATMENT OF COVID-19
43. Assessment of the endocrine-disrupting potential of halogenated parabens: An in silico approach
44. Modulation of immune responses using adjuvants to facilitate therapeutic vaccination
45. GSK669, a NOD2 receptor antagonist, inhibits thrombosis and oxidative stress via targeting platelet GPVI
46. EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells
47. Synthesis of Conformationally Constrained d-Glu-meso-DAP Analogs as Innate Immune Agonists
48. Selective Galectin‐8N Ligands: The Design and Synthesis of Phthalazinone‐d‐Galactals.
49. Selective Monovalent Galectin‐8 Ligands Based on 3‐Lactoylgalactoside.
50. 2-aminothiazoles in drug discovery: Privileged structures or toxicophores?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.